 |
 | Acute Lymphoblastic Leukemia (ALL) |
| |  | Scoring System to Distinguish L1 and L2 Variants |
| | | Prognostic Factors in Adult ALL |
| | | Prognostic Factors in Childhood ALL |
| | | Prognostic Factors in Children with Philadelphia Chromosome Positive ALL |
| | | Prognostic Model of Den Boer et al for a Patient with Acute Lymphoblastic Leukemia Based on Chemotherapy Resistance Profiles |
| | | Grading Scheme of Kurtzberg et al for Measuring Response to Chemotherapy in Acute Leukemia |
| | | National Cancer Institute (NCI) Risk Categories for a Child with Acute Lymphoblastic Leukemia (ALL) |
| | | Risk Factors of Sancho et al for Central Nervous System Involvement in a Patient with Acute Lymphoblastic Leukemia |
| Chronic Lymphocytic Leukemias |
| |  | Binet Staging System for Chronic Lymphocytic Leukemia (CLL) |
| | | Rai Staging System for Chronic Lymphocytic Leukemia (CLL) |
| | | Hairy Cell Leukemia and the Hairy-Cell Index |
| | | Criteria for Smoldering Chronic Lymphocytic Leukemia (CLL) |
| | | Criteria of the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) for Response to Therapy in CLL |
| | | Criteria of the National Cancer Institute (NCI) Working Group for Response to Therapy in B-Cell CLL |
| | | Criteria for "Active" Chronic Lymphocytic Leukemia (CLL) and the Need for Therapeutic Intervention |
| | | Indications for Splenectomy in Chronic Lymphocytic Leukemia |
| | | Richter's Syndrome |
| | | Use of ZAP-70 and Immunoglobulin Heavy Chain Gene Mutation Status to Predict Therapy Free Survival in a Patient with Chronic Lymphocytic Leukemia |
| | | Richter Syndrome (RS) Score of Tsimberidou et al |
| | | Clinical and Laboratory Findings in Hairy Cell Leukemia |
| | | Criteria of Marti et al for Monoclonal B-Cell Lymphocytosis |
| | | Use of Abdominal CT to Evaluate a Patient with Rai Stage 0 CLL |
| | | Simplified Risk Group Assignment of Lee et al for a Patient with Chronic Lymphocytic Leukemia (CLL) |
| | | Prognostic Score of Tsimberidou et al for a Patient with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (Univeristy of Texas M.D. Anderson Cancer Center Score) |
| Acute Myeloid Leukemia (AML) |
| | | Prognostic Factors in Acute Myeloid Leukemia |
| | | French-American-British (FAB) Classification of Acute Myeloid Leukemia |
| | | Subclassification of Erythroleukemia |
| | | Prognostic Groups of Estey for Acute Myelogenous Leukemia (AML) |
| | | Distinguishing Acute Promyelocytic Leukemia (APML) from the Recovery Phase of Acute Agranulocytosis Using CD117 and CD11b Immunostaining of the Bone Marrow |
| | | Prognostic Index of Breems et al (European Prognostic Score) for an Adult Patient with Acute Myelogenous Leukemia (AML) in the First Relapse |
| | | Risk Groups of Giles et al in Patients with Acute Myelogenous Leukemia After Second Salvage Therapy |
| | | Mortality Risk Factors of Creutzig et al in Children Treated for Acute Myeloid Leukemia (AML) in the Berlin-Frankfurt-Muenster (BFM) Trials 93 and 98 |
| | | Prognostic Score of Jourdan et al for a Young Adult with Acute Myeloblastic Leukemia in First Complete Remission and without a Donor for Allogeneic Stem Cell Transplantation |
| | | Risk Factors of Johnston et al for an Isolated CNS Relapse in a Pediatric Patient with Acute Myeloid Leukemia |
| | | Risk Factors for the Development of Acute Myeloid Leukemia |
| | | Model of Kantarjain et al for Predicting Complete Response in a Patient >= 65 Years Old Treated with Intensive Chemotherapy for Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome |
| | | Model of Kantarjain et al for Predicting Induction Mortality and Overall Survival in a Patient >= 65 Years Old Treated with Intensive Chemotherapy for Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome |
| | | Prognostic Factors of Razzouk et al for a Child with Acute Myeloid Leukemia (AML) |
| | | Model of Johnson et al for Predicting Survival for an Elderly Patient with Acute Myeloid Leukemia (AML) |
| | | Model of Estey et al for Predicting Survival During Induction Therapy in a Patient Newly Diagnosed with Acute Myeloblastic Leukemia (AML) |
| | | Prognostic Factors of Rubnitz et al for a Pediatric Patient with Recurrent Acute Myeloid Leukemia |
| | | Prognostic Factors of Etienne et al for Complete Remission in an Elderly Patient Receiving Induction Chemotherapy for Acute Myeloid Leukemia (AML) |
| | | Auer Rods versus Pseudo-Auer Rods |
| | | Risk Model of Sorror et al for a Patient with Acute Myeloid Leukemia or Myelodysplasia Following Allogeneic Hematopoietic Cell Transplantation |
| | | Clinical and Laboratory Features of the Microgranular or Hypogranular Variant of Acute Promyelocytic Leukemia (M3v) |
| | | Prognostic Score of Haferlach et al for Acute Myeloid Leukemia (AML) |
| Retinoic Acid Syndrome in Patients with Acute Promyelocytic Leukemia |
| | | Retinoic Acid Syndrome in Patients with Acute Promyelocytic Leukemia |
| Multiple Myeloma: Diagnosis and Staging |
| | | Diagnosis of Monoclonal Gammopathies |
| | | Myeloma Staging System of Durie and Salmon |
| | | Myeloma Staging System of Carbone et al |
| | | Myeloma Staging System of British Medical Research Council |
| | | Myeloma Staging System of Alexanian et al |
| | | Myeloma Staging System of Southeastern Cancer Study Group |
| | | Myeloma Staging System of ALGB and ECOG |
| | | Criteria for the POEMS Syndrome |
| | | Myeloma Staging System of Pasqualetti et al |
| | | Criteria of the Chronic Leukemia-Myeloma Task Force for Evaluating the Response of Multiple Myeloma to Therapy |
| | | Myeloma Staging System of Durie and Salmon Supplemented with MRI |
| | | International Staging System of the International Myeloma Working Group (Greipp et al) for Multiple Myeloma |
| | | Prognostic Factors of Weber et al for Progression in Asymptomatic Multiple Myeloma |
| | | Risk Stratification Model of Weber et al Predicting Progression in Asymptomatic (Smoldering) Multiple Myeloma |
| | | Prognostic Factors of Rajkumar et al for Progression in a Patient with Monoclonal Gammopathy of Undetermined Significance (MGUS) |
| | | Features of Solitary Plasmacytoma |
| | | Staging System of the Southwest Oncology Group (SWOG) for a Patient with Multiple Myeloma |
| | | Diagnostic Algorithm of Shaw for Nonsecretory Plasma Cell Myeloma |
| | | Prognostic Groups of Kyle et al for Patients with Smoldering (Asymptomatic) Multiple Myeloma |
| Multiple Myeloma: Prognostic Factors |
| | | Beta-2 Microglobulin and Serum Albumin |
| | | Telopeptide |
| | | Labelling Index (LI) |
| | | Multivariate Analysis with Plasma Cell Morphology |
| | | Histologic Grading of Plasma Cell Dysplasia in Multiple Myeloma |
| | | Interleukins |
| | | RNA Index |
| | | LDH |
| | | Tumor Ploidy |
| | | Molecular Markers Used at the Mayo Clinic to Identify High-Risk Multiple Myeloma |
| | | Criteria of Greipp et al for Myeloma Cell Typing and Myeloma Classification |
| Non-Hodgkin's Malignant Lymphoma |
| | | Ann Arbor Stages of Non-Hodgkin's Lymphoma |
| | | Histologic Grading of Follicular Lymphomas |
| | | Prognostic Factors in Aggressive Malignant Lymphomas |
| | | International Prognostic Index (IPI) and Prognosis in Aggressive Non-Hodgkins Lymphoma |
| | | Prognosis in Intermediate and High Grade Non-Hodgkin's Lymphoma |
| | | Prognostic Factors in Aggressive Diffuse Non-Hodgkin's Lymphoma Before Therapy |
| | | Risk Classification for Clinical Staging of Diffuse Large Cell Lymphoma |
| | | Serologic Staging System for Diffuse Large Cell Non-Hodgkin's Lymphoma Using Initial Serum Lactate Dehydrogenase and beta-2-Microglobulin Levels |
| | | Prognostic Model of Federico et al for Follicular Lymphoma |
| | | The University of Texas M.D. Anderson Cancer Center's Tumor Score for Aggressive Lymphoma |
| | | Prognostic Factors of Wilder et al for Patients with Aggressive Lymphoma |
| | | Memorial Sloan Kettering Cancer Center Predictive Model for Advanced Diffuse Histiocytic Lymphoma |
| | | Prognostic Subgroups of Shipp et al for Diffuse Large Cell Lymphoma |
| | | 1976 SWOG Criteria for Response of Non-Hodgkins Malignant Lymphoma to Therapy |
| | | St. Jude Staging System for Burkitt's Lymphoma |
| | | Prognostic Factors in Burkitt's Lymphoma |
| | | Diagnostic Features of Microvillous Lymphomas |
| | | Prognostic Score of Ferreri et al for Primary CNS Lymphoma (IELSG Score) |
| | | Prognostic Factors of Dumontet et al for Death During Induction Chemotherapy in Patients with Aggressive Non-Hodgkin's Lymphoma |
| | | Prognostic Factors of Arcaini et al for Survival in Patients with Marginal Zone Lymphomas |
| | | Prognostic Factors of International Extranodual Lymphoma Study Group (IELSG) al for a Male with Diffuse Large Cell Lymphoma of the Testis |
| | | Prognostic Factors of Chacon et al for Patients with Splenic Marginal Zone Lymphoma |
| | | Criteria of Chacon et al for Therapeutic Response in Patients with Splenic Marginal Zone Lymphoma |
| | | Prognostic Model of Lossos et al in Diffuse Large B-Cell Non-Hodgkin's Lymphoma Using a Panel of 6 Genes |
| | | Criteria of Loggins and Urquhart for Suspecting Non-Hodgkin's Lymphoma in a Patient With a Parotid Mass |
| | | Risk Factors of Stebbing et al for Non-Hodgkin's Lymphoma in a Patient with HIV Infection |
| | | Standardized Response Criteria of Cheson et al for Therapy in Non-Hodgkin's Lymphoma |
| | | Prognostic Factors of Mournier et al from the Groupe d'Etuda des Lymphomes de l'Adulte (GELA) for Patients with Aggressive Non-Hodgkin's Lymphoma Treated by Autologous Stem Cell Transplantation (ASCT) |
| | | Risk Factors of Vougarelis and Moutsopoulos for Development of Malignant Lymphoma in a Patient with Sjogren's Syndrome |
| | | Criteria for T-Cell Rich, Histiocyte Rich Diffuse Large B-Cell Non-Hodgkin's Lymphoma |
| | | Prognostic Factors of Shenkier et al for an Immunocompetent Patient with a Primary Central Nervous System Lymphoma |
| | | Prognostic Factors of Shenkier et al for a Patient with a Primary T Cell Central Nervous System Lymphoma |
| | | The Follicular Lymphoma International Prognostic Index (FLIPI) |
| | | Immunophenotypic Markers of Berglund et al Associated with Prognosis for a Patient with Diffuse Large B-Cell Lymphoma |
| | | Prognostic Factors of Hui et al for a Patient with Mantle Cell Lymphoma |
| | | Prognostic Factors of Suzuki et al for a Patient with Blastic Natural Killer Cell (NK-Cell) Lymphoma/Leukemia |
| | | Diagnostic Features of Blastic Natural Killer Cell (NK-Cell) Lymphoma/Leukemia |
| | | Criteria of Boulanger et al for the Diagnosis of a Primary Effusion Lymphoma Associated with Human Herpesvirus 8 (HHV-8) |
| | | Prognostic Factors of Boulanger et al for AIDS-Associated Primary Effusion Lymphoma (PEL) |
| | | Risk Factors of Lyman et al for the Failure to Adequately Treat a Patient with an Aggressive Non-Hodgkin's Lymphoma |
| | | Clinical Features of Intravascular Anaplastic Large Cell Malignant Lymphoma |
| | | Prognostic Model of Lee et al for Extranodal Natural Killer/T (NK/T) Cell Lymphoma of the Nasal Type |
| | | Guidelines of the International Primary CNS Lymphoma Collaboratrive Group for Therapeutic Response |
| | | Clinical-Pathologic Prognostic Score of Went et al for a Patient with Peripheral T-Cell Lymphoma |
| | | Prognostic Model of Gallamini et al for a Patient with a Peripheral T-Cell Lymphoma |
| | | Prognostic Model of Hoskins et al for a Patient with Diffuse Large Cell Lymphoma Treated with MACOP-B |
| | | Risk Factors of Smedby et al for Malignant Non-Hodgkin Lymphoma in a Patient with Rheumatoid Arthritis |
| | | Prognostic Factors of Lim et al for HIV-Related Diffuse Large-Cell Non-Hodgkin's Lymphoma |
| | | Prognostic Model of Arcaini et al for a Splenic Marginal Zone Lymphoma |
| | | Prognostic Factors of Parry-Jones et al for Splenic Lymphoma with Villous Lymphocytes |
| | | Prognostic Model of Low et al for a Patient with Grade II Non-Hodgkin's Lymphoma |
| | | Criteria of Quintanilla-Martinez for Fulminant Epstein-Barr Virus (EBV) Positive T-Cell Lymphoproliferative Disorder |
| | | Memorial Sloan-Kettering Cancer Center (MSKCC) Prognostic Model for Primary CNS Lymphoma |
| | | Nottingham/Barcelona Prediction Score for Primary Non-Hodgkin's Lymphoma of the CNS |
| | | Prognostic Factors of Laskar et al for a Patient with Primary Diffuse Large B-Cell Lymphoma of the Tonsil |
| | | Criteria of Solal-Celigny et an for High Tumor Burden in a Patient iwth Malignant Non-Hodgkin's Lymphoma |
| | | Colorectal Lymphomatous Polyposis |
| Hodgkin's Disease |
| | | Prognostic Score of the International Prognostic Factors Project for Patients with Advanced Hodgkin's Disease |
| | | A Numerical Prognostic Index to Identify Poor Risk Patients with Hodgkin's Disease at Diagnosis |
| | | Predictive Equation for Prognosis in Hodgkin's Disease of Gobbi et al |
| | | Additional Analysis of Prognosis in Hodgkin's Disease Using the Predictive Equation of Gobbi et al |
| | | Estimate for Expected Survival at Diagnosis in Hodgkin's Disease of Gobbi et al |
| | | Criteria of the European Organization for Research and Treatment of Cancer Groupe d'Eude des Lymphomes de l'Adulte (EORTC-GELA) for Favorable Prognostic Groups of Hodgkin's Disease |
| | | Prognostic Factors of Straus et al for Patients with Advanced Hodgkin's Disease |
| | | Prognostic Factors of Wagstaff et al for Patients with Stage IIIB and IV Hodgkin's Disease |
| | | Manchester Index of Lee et al for Identifying Risk of Progression in Patients with Hodgkins Disease |
| | | Integrated Index of Gobbi et al for Patients with Advanced Hodgkin's Disease |
| | | Prognostic Index of Smith et al for Children with Hodgkin's Disease Receiving Combined Modality Therapy |
| | | Histologic Grades of MacLennan et al for Nodular Sclerosing Hodgkin's Disease |
| | | Prognostic Score of Josting et al for Patients with Relapsed Hodgkin's Lymphoma |
| | | Prognostic Score of Sup et al for Patients with Classical Hodgkin's Lymphoma |
| | | Prognostic Factors of Wirth et al for a Patient with Lymphocyte Predominant Hodgkin's Disease Treated with Radiation Therapy Alone |
| | | Grading Scheme of von Wasielewski et al for Nodular Sclerosing Hodgkin Disease |
| | | Clinical Prediction Rule of Vassilakopoulos et al for Predicting Bone Marrow Involvement in a Patient with Hodgkin's Disease |
| | | Prognostic Model of Low et al for a Patient with Hodgkin's Disease |
| | | Prognostic Scoring System of Maurcort-Boulch et al for a Patient with Hodgkin's Disease |
| | | Plasma Cytokine Signature Score of Casasnovas et al for Predicting Outcome in a Patient with Classic Hodgkin's Disease |
| Histiocytic Syndromes |
| | | Lahey's Definition of Organ Dysfunction in Histiocytosis X |
| | | The Southwest Oncology Group Staging System for Histiocytosis X |
| | | Histiocytosis Grouping System of Osband et al. |
| | | Factors Predictive of Progressive Disease in Patients with Langerhans Cell Histiocytosis |
| Chronic Myeloproliferative Disorders: Primary Thrombocythemia (Essential Thrombocythemia) |
| | | Criteria for the Diagnosis of Primary Thrombocythemia |
| | | Diagnostic Scoring System for Primary Thrombocythemia of Dudley et al |
| | | Approach of Schafer for Management of Primary (Clonal) Thrombocythemia |
| | | Treatment Algorithm of Tefferi and Barbui for a Patient with Essential Trombocythemia |
| | | Risk Classification of Tefferi and Barbui for a Patient with Essential Thrombocythemia |
| | | Risk Factors of Wolanskyj et al for Thrombotic Complications in a Patient with Essential Thrombocythemia |
| | | Risk Factors of Wolanskyj et al for Mortality in a Patient with Essential Thrombocythemia |
| | | Criteria of Campbell and Green for Primary Thrombocythemia Based on JAK2 Status |
| Chronic Myeloproliferative Disorders: Polycythemia Rubra Vera |
| | | Polycythemia Vera Study Group Criteria for Diagnosis |
| | | Criteria of Hoffman and Boswell for Polycythemia Vera |
| | | Flow Chart of Barbui and Finazzi for Therapy Selection in Polycythemia Vera |
| | | Treatment Algorithm of Tefferi for a Patient with Polycythemia Vera |
| | | Risk Classification of Tefferi and Barbui for a Patient with Polycythemia Vera |
| | | Criteria of Tefferi and Barbui for the Diagnosis of Polycythemia Vera |
| | | Criteria of Campbell and Green for Polycythemia Based on JAK2 Status |
| Chronic Myeloproliferative Disorders: Chronic Myelogenous Leukemia (CML) |
| | | Synthesis Prognostic Staging System for CML |
| | | Prognostic Score 1 in CML |
| | | Regression Models of Kantarjian et al for Predicting Survival in CML |
| | | Relative Risk Equation of Sokal et al for Patients with Chronic Myelogenous Leukemia (CML) |
| | | Relative Hazard Equation of Cervantes and Rozman for Patients with Chronic Myelogenous Leukemia (CML) |
| | | Prognostic Score of Hasford et al for Patients with Chronic Myeloid Leukemia Treated with Interferon Alfa |
| | | Negative Prognostic Factors of the Italian Cooperative Study Group for Staging Chronic Myeloid Leukemia |
| | | Morphometric Bone Marrow Risk Classification Method of Kvasnicka et al for Patients with Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML) |
| | | Features of Atypical Chronic Myeloid Leukemia (aCML) in the WHO Classification of Mixed Myelodysplastic and Myeloproliferative Disorders |
| | | Prognostic Score of Onida et al for Philadelphia Chromosome Negative, bcr/abl Negative Chronic Myelogenous Leukemia (CML) |
| | | Criteria of the WHO Classification for the Accelerated and Blastic Phases of Chronic Myelogenous Leukemia (CML) |
| | | Criteria for Therapeutic Response in Patients with Chronic Myelogenous Leukemia (CML) in the Chronic or Accelerated Phase |
| | | The European Group for Bone Marrow Transplant (ÆEBMT) Risk Score for a Patient with Chronic Myeloid Leukemia Following Marrow or Stem Cell Transplant |
| | | The Risk Score of Passweg et al for the First Chronic Phase of CML (CML-CP Score) |
| | | Model of Kantarjian et al for Predicting a Complete Cytogenetic Response to Imatinib Mesylate in a Patient with Philadelphia Chromosome Positive Chronic Phase CML |
| | | Morphological Score of Lugli et al for Monitoring the Response of a Patient with Chronic Myelogenous Leukemia (CML) to Imatinib Mesylate |
| Chronic Myeloproliferative Disorders: Agnogenic Myeloid Metaplasia (Myelofibrosis with Myeloid Metaplasia) |
| | | Prognostic Groups of Visani et al in Myelofibrosis with Myeloid Metaplasia |
| | | Prognostic Score of Hasselbalch and Jensen in Idiopathic Myelofibrosis |
| | | Criteria for the Diagnosis of Myelofibrosis with Myeloid Metaplasia |
| | | Prognostic Classes of Njoku et al in Myelofibrosis with Myeloid Metaplasia |
| | | Factors of Cervantes et al for the Identification of Low and High Risk Prognostic Groups in Idiopathic Myelofibrosis |
| | | Prognostic Classification of Barosi et al for Myelofibrosis with Myeloid Metaplasia |
| | | Prognostic Factors of Kvasnicka et al for Idiopathic Osteomyelofibrosis |
| | | The Lille Scoring System of Dupriez et al for Predicting Survival in Agnogenic Myeloid Metaplasia |
| | | Severity Score of Barosi et al for Myelofibrosis with Myeloid Metaplasia (Myelodepletive and Myeloproliferative Indices) |
| | | Risk Classification of Tefferi and Barbui for Myelofibrosis with Myeloid Metaplasia |
| | | CBC-Based Scoring System of Dingli et al for a Patient with Agnogenic Myeloid Metaplasia |
| | | Guidelines of Tefferi and Deeg for Therapy in a Patient with Myelofibrosis and Myeloid Metaplasia |
| | | Criteria of Campbell and Green for Myelofibrosis Based on JAK2 Status |
| | | Score of Elliott et al for Survival in Primary Myelofibrosis (New Mayo Score) |
| Waldenstrom's Macroglobulinemia |
| | | Scoring System of Morel et al for Waldenstrom's Macroglobulinemia |
| | | Prognostic Score of Gobbi et al for Waldenstrom's Macroglobulinemia |
| | | Prognostic Factors of Facon et al for Waldenstrom's Macroglobulinemia |
| | | Prognostic Factors and Diagnostic Criteria of Owen et al for Waldenstrom's Macroglobulinemia |
| | | Prognostic Score of Baldini et al for Predicting Evolution of Asymptomatic Macroglobulinemia (IgM MGUS or Indolent Waldenstrom's Macroglobulinemia) |
| | | Prognostic Models of Ghobrial et al for a Newly Diagnosed Patient with Symptomatic Waldenstrom's Macroglobulinemia |
| Syndromes Associated with High White Blood Cell Counts in Leukemias (Hyperleukocytic Syndromes) |
| | | Viscosity in Patients with Leukemia |
| | | Hyperviscosity Syndrome in Patients with Leukemia |
| | | Leukostasis in Patients with Leukemia |
| | | Pseudohypoxemia in Patients with Hyperleukocytosis |
| Cutaneous Lymphoma |
| | | Tumor Burden Index in Cutaneous T-Cell Lymphoma |
| | | TNM Staging of Cutaneous T-Cell Lymphoma |
| | | Histopathologic Criteria of Cox for Mycosis Fungoides |
| | | The Severity-Weighted Assessment Tool (SWAT) for Mycosis Fungoides |
| | | Prognostic Features of Gniadecki et al for CD56-Positive Extranodal Lymphoma with Cutaneous Involvement |
| | | Cutaneous B-Cell Lymphoma Prognostic Index of Smith et al |
| | | Pseudo-Sezary Syndrome in a Patient with AIDS |
| | | Clinical and Laboratory Features of Sezary Syndrome |
| | | Grading Lymph Node Involvement in Mycosis Fungoides or Sezary Syndrome |
| | | Clinical Features of Primary Cutaneous Diffuse Large B-Cell Lymphoma of the Leg Type |
| Acute Tumor Lysis Syndrome (TLS) |
| | | Acute Tumor Lysis Syndrome in Malignant Lymphoma or Lymphocytic Leukemias |
| | | Penn Predictive Score of Tumor Lysis Syndrome (PPS-TLS) in Acute Myelogenous Leukemia |
| | | Grading Classification of Cairo and Bishop for the Tumor Lysis Syndrome |
| | | Predictive Factors of Truong et al for Tumor Lysis Syndrome in a Pediatric Patient with Acute Lymphoblastic Leukemia (ALL) |
| Cytochemical and Immunohistochemical Stains for the Diagnosis of Leukemia |
| | | Evaluation of Acute Leukemia with Positive Peroxidase or Sudan Black B Stains |
| | | Evaluation of Acute Leukemia Negative for Peroxidase, Sudan Black B and Esterase Stains |
| | | Subclassification of Acute Lymphoblastic Leukemia Using Immunocytochemical Stains |
| | | The European Group for the Immunological Classification of Leukemias Scoring System for Identification of Biphenotypic Acute Leukemia (BAL) |
| | | Scoring System of Thalhammer-Scherrer et al in Adult Acute Leukemia |
| | | Scoring System of Moreau et al for Distinguishing CLL from Other B-Cell Lymphoproliferative Disorders |
| Angioimmunoblastic Lymphadenopathy |
| | | Prognostic Factors of Archimbaud et al in Angioimmunoblastic Lymphadenopathy |
| Plasma Hyperviscosity |
| | | Symptoms Associated with Plasma Hyperviscosity |
| | | Indications for Plasmapheresis in Patients with Plasma Hyperviscosity |
| Hemophagocytic Lymphohistiocytosis and the Hemophagocytic Syndromes |
| | | Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis |
| | | Prognostic Factors for Adults with the Hemophagocytic Syndrome |
| | | 2004 Update to the Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis (HLH) |
| | | Criteria of Ravelli et al for the Macrophage Activation Syndrome (MAS) in a Patient with Systemic Juvenile Idiopathic Arthritis |
| Proliferations of Large Granular Lymphocytes |
| | | Classification of McDaniel et al for Lymphoproliferative Disorders of Granular Lymphocytes (LDGL) |
| | | Algorithm of Lamy and Loughram for Evaluation of Large Granular Lymphocytosis in the Blood |
| Transient Myeloproliferative Disorder in Newborns with Trisomy 21 (Down Syndrome) |
| | | Transient Myeloproliferative Disorder in Newborns with Trisomy 21 (Down Syndrome) |
| Lymphomatoid Granulomatosis (LYG, Angiocentric Lymphoproliferative Disorder) |
| | | Grading Scheme of Lipford et al for Lymphomatoid Granulomatosis |
| Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma |
| | | Classification Scale of Wotherspoon et al for Gastric MALT Lymphoma |
| | | TNM Staging of Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma |
| Posttransplantation Lymphoproliferative Disorders (PTLD) |
| | | Risk Factors of Curtis et al for Posttransplantation Lymphoproliferative Disorders in Patients After Bone Marrow Transplantation |
| | | Criteria of Preiksaitis and Keay for Clonality and Epstein-Barr Virus (EBV) Status in Posttransplant Lymphoproliferative Disorder |
| | | Risk Factors of Preiksaitis and Keay for Posttransplant Lymphoproliferative Disorder |
| | | Prognostic Score of Ghobrial et al for an Adult with a Solid Organ Transplant and Post-Transplantation Lymphoproliferative Disorder |
| Plasma Cell Leukemia |
| | | Plasma Cell Leukemia |
| Heavy Chain Diseases |
| | | Clinical Features of Alpha Heavy Chain Disease (Mediterranean Abdominal Lymphoma) |
| | | Clinical Features of Gamma Heavy Chain Disease (Franklin's Disease) |
| | | Clinical Features of Mu Heavy Chain Disease |
| Extensive Sarcoid-Like Granulomas in a Patient with a Lymphoproliferative Disorder (Sarcoidosis-Lymphoma Syndrome) |
| | | Extensive Sarcoid-Like Granulomas in a Patient with a Lymphoproliferative Disorder (Sarcoidosis-Lymphoma Syndrome) |
| | | Malignancy-Sarcoidosis Syndrome |
| Amyloidosis Complicating Plasma Cell Disorders |
| | | Staging System of Dispenzieri et al for Primary Systemic Amyloidosis Based on Cardiac Troponin and pro-BNP Serum Levels |
| | | Risk Score of Dispenzieri et al for Primary Systemic Amyloidosis |
| | | Unfavorable Prognostic Factors of Kyle et al for a Patient with Primary Amyloidosis |
| | | Prognostic Factors of Moreau et al for Survival After Autologous Stem Cell Transplantation of a Patient with Systemic AL Amyloidosis |
| | | Risk Groups of Kyle et al for Survival in Patients with Primary Systemic Amyloidosis |
| | | Criteria of Gertz et al for Therapeutic Response in a Patient with Primary Systemic Amyloidosis |
| | | Criteria of Kyle et al for Therapeutic Response in a Patient with Primary Systemic Amyloidosis |
| | | Clinical Findings That Should Alert the Clinician to the Possibility of Amyloidosis |
| |
| TOP |